Guanfacine Tablet, Extended Release
NDC Package 70518-4539-0

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Guanfacine tablets is guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies ( 14)]. This formulation utilizes a tablet, extended release delivery system. Marketed by Remedyrepack Inc., this product is identified by NDC 70518-4539 and is authorized under FDA application ANDA219033.

Identification & Billing

NDC Package Code
70518-4539-0
Package Description
30 TABLET, EXTENDED RELEASE in 1 BLISTER PACK
Product Code
70518-4539
11-Digit Billing Format
70518453900
RxNorm Crosswalk
  • RxCUI: 862006 - guanFACINE 1 MG 24HR Extended Release Oral Tablet
  • RxCUI: 862006 - 24 HR guanfacine 1 MG Extended Release Oral Tablet
  • RxCUI: 862006 - guanfacine 1 MG (as guanfacine hydrochloride 1.14 MG) 24 HR Extended Release Oral Tablet
  • RxCUI: 862006 - guanfacine 1 MG (as guanfacine hydrochloride 1.15 MG) 24 HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Guanfacine
Non-Proprietary Name
Guanfacine
Substance Name
Guanfacine Hydrochloride
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
GUANFACINE HYDROCHLORIDE 1 mg/1
Pharmacologic Class
Usage Information
Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies ( 14)].

Regulatory & Marketing

Labeler Name
Remedyrepack Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA219033
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
12-23-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70518-4539-0 identifies a specific commercial package of 30 tablet, extended release in 1 blister pack of Guanfacine, a human prescription drug labeled by Remedyrepack Inc.. This tablet, extended release is formulated for oral use and contains guanfacine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Remedyrepack Inc. on December 23, 2025. The current certification is valid through December 31, 2027.

How is this Remedyrepack Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70518453900. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70518-4539-0
11-Digit CMS (5-4-2)
70518-4539-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.